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Increasing evidence supports the idea of a beneficial effect of cannabinoid compounds for the treatment of multiple sclerosis (MS).
However,most experimental data come fromanimalmodels ofMS.We investigated the status of cannabinoid CB1 andCB2 receptors and
fatty acid amide hydrolase (FAAH) enzyme in brain tissue samples obtained from MS patients. Areas of demyelination were identified
and classified as active, chronic, and inactive plaques. CB1 and CB2 receptors and FAAH densities and cellular sites of expression were
examinedusing immunohistochemistry and immunofluorescence. InMS samples, cannabinoidCB1 receptorswere expressedby cortical
neurons, oligodendrocytes, and also oligodendrocyte precursor cells, demonstrated using double immunofluorescence with antibodies
against the CB1 receptor with antibodies against type 2 microtubule-associated protein, myelin basic protein, and the platelet-derived
growth factor receptor-, respectively. CB1 receptors were also present in macrophages and infiltrated T-lymphocytes. Conversely, CB2
receptorswere present in T-lymphocytes, astrocytes, and perivascular and reactivemicroglia (major histocompatibility complex class-II
positive) in MS plaques. Specifically, CB2-positive microglial cells were evenly distributed within active plaques but were located in the
periphery of chronic active plaques. FAAH expression was restricted to neurons and hypertrophic astrocytes. As seen for other neuroin-
flammatory conditions, selective glial expression of cannabinoid CB1 and CB2 receptors and FAAH enzyme is induced in MS, thus
supporting a role for the endocannabinoid system in the pathogenesis and/or evolution of this disease.
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Introduction
Cannabis sativa preparations have been used for4000 years for
recreational and medicinal purposes, but the mechanistic char-
acterization of some of its constituent chemicals, the “cannabi-
noids,” is muchmore recent (Mechoulam et al., 1994; Porter and
Felder, 2001). To date, two cannabinoid receptors have been
cloned, the CB1 and the CB2 receptors (Matsuda et al., 1990;
Munro et al., 1993). In addition, several endocannabinoids
have been identified, most important among them are N-
arachidonoylethanolamine [anandamide (AEA)] and 2-arachi-
donoylglycerol (Mechoulam et al., 1998). These endocannabi-
noids are synthesized and released on demand and, after release,
are removed from their sites of action by cellular uptake pro-
cesses. The endocannabinoids are metabolized intracellularly by
fatty acid amide hydrolase (FAAH) and monoglyceride lipase,
among other enzymes (Bisogno et al., 2005).
Currently, the endocannabinoid system (ECS) is a target for
the treatment of several diseases, including multiple sclerosis
(MS) (Pryce and Baker, 2005). Clinical evidence confirms the
therapeutic potential of cannabinoids in the treatment of symp-
toms of MS. A randomized, placebo-controlled trial in which
patients with both stable MS and muscle spasticity were treated
with cannabis extract or9-tetrahydrocannabinol (9-THC) for
15 weeks found that the drug treatments did not reduce the spas-
ticity using objective measures, although patients reported im-
provements (Zajicek et al., 2003). Patients who continued 9-
THC treatment for up to 12months did exhibit a small reduction
in objective measures of spasticity (Zajicek et al., 2005). Patients
also reported a reduction in pain together with improvements in
mobility (Zajicek et al., 2005). Another clinical trial using the
oromucosal spray Sativex (a combination of 9-THC and can-
nabidiol) to treat central neuropathic pain syndromes attribut-
able to MS showed that this preparation produced a significant
reduction in pain and sleep disturbances (Rog et al., 2005).
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Results from studies in animal models support the hypothesis
that activation of the ECS can relieve certain signs of disease of
MS. For example, 9-THC administration delayed the onset of
the disease and remarkably reduced CNS inflammation in exper-
imental autoimmune encephalomyelitis (EAE) (Lyman et al.,
1989). In addition, administration of synthetic cannabinoids
ameliorated the tremor and spasticity in mice with chronic re-
lapsing EAE, through a CB1-mediated mechanism (Baker et al.,
2000). Cannabinoid receptor agonists also improved neurologi-
cal deficits in the Theiler’s murine encephalitis virus model as a
result of both a reduction in CNS inflammation and extensive
remyelination (Arevalo-Martin et al., 2003).
Interestingly, Eljaschewitsch et al. (2006) have reported re-
cently that AEA levels are increased in human active MS lesions.
To our knowledge, only one immunohistochemical study of can-
nabinoid receptors in human MS samples has been published
(Yiangou et al., 2006). This study, performed using spinal cord,
found strong CB2 immunoreactivity in microglia/macrophages
in whitematter areas inMS sections, usually within or at the edge
of plaque areas (Yiangou et al., 2006). These results confirm pre-
vious reports that CB2 receptors are expressed by CNS glial cells
and in healthy human brains (Nunez et al., 2004) and that CB2
receptor expression is upregulated by neuroinflammation (Be-
nito et al., 2003, 2005).
Materials andMethods
Tissues. Postmortem brain tissues from MS donors (n  6; age range,
54–72 years) and controls with no background of neuropsychiatric dis-
ease (n 2; 60 and 76 years) were provided by the UKMultiple Sclerosis
Tissue Bank (Table 1). Cortical and periventricular brain samples were
fixed in Formalin, embedded in paraffin, and cut into 4-m-thick sec-
tions for the immunohistochemical study.
Classification of MS plaques. To identify regions of demyelination in
MS tissue samples, Luxol fast blue staining was performed. Lesions were
classified according to Trapp et al. (1999) by performing immunohisto-
chemistry of the D-region-related–human leukocyte-associated antigen
(HLA-DR), a member of the class II of the major histocompatibility
complex (MHC-II). We defined three main categories of demyelinated
lesions or “plaques” based on the distribution and density of inflamma-
tory cells and activated microglia (MHC-II positive). “Active” plaques
exhibit abundant and evenly distributed HLA-DR-positive cells. Cells
within the lesioned area are mostly large, round, and lipid-laden macro-
phages. These lesions are thought to be relatively recent (2–3 months)
(Trapp et al., 1999). If phagocytes contain myelin protein debris, the
plaques are considered even more recent (2–3 weeks). Conversely,
“chronic” plaques are characterized by an enrichment of HLA-DR-
positive, lipid-laden macrophages at the border of the lesion. Finally,
“inactive” lesions contain very few HLA-DR-positive cells.
Immunohistochemistry. The protocol used was as described previously
(Tsou et al., 1998; Benito et al., 2003, 2005), with slight modifications.
Tissue sections were deparaffinized and washed extensively in 50 mM
potassium–PBS (KPBS). To obtainmore efficient immunostaining, sam-
ples were subjected to an antigen retrieval procedure (Shi et al., 2001).
Briefly, tissue sections were placed into a stainless-steel pressure cooker
containing Antigen Retrieval Solution (DakoCytomation, Glostrup,
Denmark). After heating under pressure for 2 min, samples were re-
moved and washed extensively in KPBS. Then, endogenous peroxidase
was blocked by 30 min incubation at room temperature in peroxidase-
blocking solution (DakoCytomation). After several washes with KPBS,
tissues were incubated with primary antibody (Table 2) overnight at 4°C.
Antibodies were diluted in KPBS containing 1% BSA (Sigma, St. Louis,
MO) and 1% Triton X-100 (Sigma). After the incubation, sections were
washed in KPBS, followed by incubation with biotinylated goat anti-
rabbit antibody (1:200) (for polyclonal antibodies) or biotinylated horse
anti-mouse antibody (1:200) (for monoclonal antibodies) for 1 h at
room temperature. Avidin–biotin complex (Vector Elite; Vector Labo-
ratories, Burlingame, CA) and a diaminobenzidine substrate–chromo-
gen system (DakoCytomation) were used to obtain a visible reaction
product. Controls for the immunohistochemistry included preabsorp-
tion and coincubation of the antibodies with the corresponding immu-
nogenic proteins (when available) as described in previous studies (Be-
nito et al., 2003, 2005). Sections were dehydrated, sealed, and
Table 1. Summary of brain samples used for immunohistochemistry and histopathological studies
Lesional activity
Patients Age (years)/sex Diagnosis Postmortem interval (h) Number of blocks examined Number of MS lesions Active Chronic Inactive
MS96 58/F SPMS 36 5 7 4 3
MS110 54/F SPMS 18 5 33 15 9 9
MS123 63/M SPMS 12 5 9 6 1 2
MS132 72/F SPMS 23 5 4 1 3
MS152 55/F SPMS 36 5 2 1 1
MS177 60/F SPMS 24 5 11 4 6 1
C17 76/F Normal 74 2 ND ND ND ND
C18 60/F Normal 44 2 ND ND ND ND
Total 34 66 31 22 13
F, Female; M, male; MS multiple sclerosis; SPMS, secondary progressive multiple sclerosis; C, control; ND, nondetectable.
aLesional activity was determined by histological examination and divided into three categories: active, chronic, and inactive as described in Materials and Methods.
Table 2. Antibodies used in the study
Antibody Target Dilution (IHC) Dilution (IF) Class Manufacturer
HLA-DR Microglia/macrophages (MHC-II) 1:200 1:100 Monoclonal DakoCytomation
CD68 Macrophages 1:100 Monoclonal DakoCytomation
CD3 T-lymphocytes 1:50 1:50 Monoclonal DakoCytomation
GFAP Astrocytes 1:200 Monoclonal Sigma
MAP-2 Neurons 1:200 Monoclonal Calbiochem (La Jolla, CA)
PDGFR- Oligodendrocyte precursor cells 1:100 Monoclonal BD PharMingen (San Diego, CA)
MBP Adult oligodendrocytes/myelin debris 1:500 Monoclonal Sternberger Monoclonals (Lutherville, MD)
CB1 Residues 1–99 of N-terminal of human CB1 protein 1:300 1:100 Polyclonal Affinity BioReagents (Golden, CO)
CB2 Residues 1–33 of N-terminal of human CB2 protein 1:300 1:100 Polyclonal Affinity BioReagents
FAAH Residues 561–579 of C-terminal of rat FAAH protein 1:50 1:50 Polyclonal C. J. Hillard
IHC, Immunohistochemistry, IF immunofluorescence.
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coverslipped. A Nikon (Tokyo, Japan) Eclipse 90i microscope and
DXM1200F camera were used for the observations and photography of
the slides, respectively.
Immunofluorescence. To identify specific cell populations, we per-
formed colocalization studies with immunofluorescence together with
specific markers for macrophages, microglia, astrocytes, neurons,
T-lymphocytes, and oligodendrocytes (Table 2). After the antigen re-
trieval procedure, tissue sections were washed with Tris-buffered saline
(TBS) before overnight incubation at 4°C with the monoclonal antibod-
ies used for identification of the cell types (Table 2), followed by incuba-
tion with an Alexa 546 anti-mouse antibody conjugate (Invitrogen,
Carlsbad, CA) at 37°C for 2 h, rendering red fluorescence. Afterward, the
primary antibodies for CB1, CB2, or FAAH were incubated overnight at
4°C after extensive washes in TBS, followed by incubationwith Alexa 488
anti-rabbit antibody conjugate (Invitrogen), rendering green fluores-
cence. FAAH was visualized by incubation with biotinylated anti-rabbit
secondary antibody, followed by streptavidin–Alexa 488 conjugate (In-
vitrogen), as described previously (Nunez et al., 2004). To quench en-
dogenous autofluorescence, tissue sections were treated with 1% Sudan
Black in 70% ethanol for 5 min and differentiated with 70% ethanol
(Schnell et al., 1999). Sections weremounted onto glass slides with aque-
ous solution (Vectashield; Vector Laboratories). A Nikon Eclipse 90i
microscope and DXM1200F camera were used for the observations and
photography of the slides, respectively.
Results
Characteristics of MS plaques status and cellular composition
No areas of demyelination were observed in control samples. In
control cases, CB1 and FAAH expression was limited to neuronal
elements of the cortex, whereas CB2 receptors were almost unde-
tectable (data not shown). Conversely, a total of 66 plaques were
identified in the samples from patients with MS, as described in
Table 1. Using HLA-DR-positive cell density and distribution in
the plaques as our criteria (Fig. 1), as described in Materials and
Methods, 31 of the plaques were classified as “active,” 22 as
“chronic,” and 13 as “inactive.” A semiquantitative analysis of the
expression of CB1, CB2, and FAAH proteins was performed (Ta-
ble 3). The number of positive cells per section was counted and
grouped according to cell subtypes based on the expression of
phenotypic markers: neurons [microtubule-associated protein
2-positive (MAP-2)], astrocytes [glial fibrillary acidic protein-
positive (GFAP)], oligodendrocyte precursor cells (OPCs)
[identified as platelet-derived growth factor receptor--positive
(PDGFR-)], adult oligodendrocytes [myelin basic protein-
positive (MBP)], microglia [HLA-positive (HLA)], macro-
phages (CD68), and T-lymphocytes (CD3). CB1 and CB2 im-
munoreactivities were observed in active and chronic MS
plaques, whereas FAAH was only evident in active plaques. Inac-
tive plaqueswere devoid of immunostaining for thesemarkers, in
concordancewith the extremely low cellularity of these patholog-
ical structures (Table 3).
CB2 receptors in MS
CB2 receptor immunoreactivity was restricted to cells located
within active plaques (Fig. 1A,B) and cells located in the periph-
ery of chronic lesions (Fig. 1C,D). Inactive plaques exhibited no
staining for the CB2 receptor (Fig. 1E,F). The CB2-positive cells
were morphologically similar and showed identical distribution
to microglial HLA-DR-positive cells in the plaques (Fig. 1). This
coincidence was confirmed by double immunostaining with
HLA-DR (Fig. 2A–C). In addition, macrophages (CD68) were
positive for CB2 receptor immunoreactivity (Fig. 2D–F). Impor-
tantly, a fraction of the CB2 positive-macrophages also contained
MBP (Fig. 2G–I), indicating recent phagocytic activity and sug-
gesting that CB2 receptor expression in plaque-associated mac-
rophages is an early event in plaque evolution. GFAP fluores-
cence immunostaining also revealed that CB2-positive astrocytes
were present in white matter areas (Fig. 2 J–L). Finally, perivas-
cular T-lymphocytes exhibited intense CB2 receptor immunore-
activity (Fig. 2M–O). No CB2 receptor was observed in cortical
neuronal elements.
CB1 receptors in MS
As expected, the CB1 receptor was abundantly expressed in cor-
tical neurons and, specifically, in large pyramidal cells of both
control and MS samples (data not shown). Additionally, CB1
receptor immunoreactivity was also detected in neurons located
in white matter areas (Fig. 3A,B), as revealed by double-
immunofluorescence staining with MAP-2 (Fig. 3D–F). This
stainingwasmore evident in demyelinated areas, probably attrib-
utable to decreased interference from axonal staining. Intense
staining for the CB1 receptor was also observed in non-neuronal
cell types. Remarkably, adult oligodendrocytes and OPCs in ac-
tive plaques, identified with the specific markers MBP and
PDGFR-, were also immunoreactive for the CB1 receptor (Fig.
3G–I,J–L). Importantly, not all active lesions contained CB1-
positive adult oligodendrocytes or OPCs. In addition, double-
labeling experiments with CD68 demonstrated abundant CB1-
positive macrophages within active plaques (Fig. 3C,M–O).
Finally, perivascular T-lymphocytes also exhibited staining for
CB1 receptors (Fig. 3P–R).
Figure 1. Distribution of CB2-positive cells (right column) compared with that of HLA-DR-
positive cells (left column) in the three different types of MS plaques (delineated with dashed
lines). A–F, The morphology and distribution of CB2-positive cells in an active (B) and chronic
(D) plaques were nearly identical to those of HLA-DR-positive microglia (see insets; A, C). No
CB2-positive cells were evident in inactive plaques (E, F ). Luxol fast blue staining (blue) com-
bined with immunostaining (brown). Scale bar: A–F, 500m; insets, 20m.
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FAAH in MS
FAAH expression was observed in cortical neurons in both con-
trol andMS samples (data not shown). Contrary to the pattern of
CB1 receptor expression, FAAH was not detected in subcortical
white matter neurons. In MS tissue samples, FAAH expression
was evident only in plaques of the active type (Fig. 4A). These
FAAH-positive cells exhibited strong immunoreactivity in cell
bodies, whereas processes were weakly immunoreactive (Fig.
4B). High-magnification pictures re-
vealed an astrocyte-like morphology (Fig.
4B) that was confirmed by double staining
with GFAP (Fig. 4C–E).
Discussion
MS is an inflammatory, demyelinating
disease of the CNS and is a major cause of
neurological disability among young
adults (Noseworthy et al., 2000). The
characteristic symptoms of this disease
(such as painful muscle spasms, tremor,
ataxia, weakness, or paralysis) are thought
to be the result of both newly formed CNS
lesions and expansion of old lesions.
Neuropathology of MS includes axonal
degeneration, oligodendrocyte loss, and
subsequent induction of areas of demyeli-
nation. Lymphocytes and monocytes in-
filtrate the white matter surrounding the
blood vessels, destroying myelin but usu-
ally sparing axons. Finally, cells of mono-
cytic origin are responsible for myelin re-
moval by phagocytosis and contribute to
the inflammatory process (for review, see
Noseworthy et al., 2000).
The ECS is a putative target for the de-
velopment of new therapeutic tools for the
treatment ofMS. Despite relevant preclin-
ical data obtained in the past few years, the
status of the ECS in human MS remains
unstudied. To that end, we performed an
extensive immunohistochemical analysis
of the changes in cannabinoid CB1 and
CB2 receptors and in the FAAH enzyme in
tissue samples from MS donors. Our re-
sults show that, as with other human neu-
roinflammatory diseases, profound alter-
ations in the expression profile of these
elements of the ECS occur in the brains of
MS patients compared with normal pa-
tients. The current data support the hy-
pothesis suggested previously that a shift
in the ECS from predominantly neuronal
to glial occurs in neuroinflammation (Pa-
zos et al., 2005).
Neuronal expression was only evident for CB1 and FAAH,
mostly on pyramidal neurons. CB1 receptors, but not FAAH,
were also detected in subcortical white matter neurons, as re-
vealed by double-immunofluorescent labeling withMAP-2. This
observation suggests a regional segregation in the pattern of CB1
and FAAH expression. CB1 receptors located on glutamatergic
neurons could exert a direct neuroprotective effect by dampening
Table 3. Relative abundance of CB1 and CB2 cannabinoid receptors and FAAH in specific cell subpopulations in active and chronic MS lesions
Active lesions Chronic lesions
HLA-DR CD68 GFAP PDGFR- MBP CD3 MAP-2 HLA-DR CD68 GFAP PDGFR- MBP CD3 MAP-2
CB1   ND     ND ND ND ND ND  
CB2    ND ND  ND  ND ND ND ND  ND
FAAH ND ND  ND ND ND ND ND ND ND ND ND ND ND
Data shown are the number of positive cells for twomarkers in at least three sections per case.,10 cells/tissue section;, 10–25 cells/tissue section;, 25–50 cells/tissue section;,50 cells/tissue section; ND,
nondetectable.
Figure 2. Double-immunofluorescence assays of CB2-positive cells (left column) and phenotypic markers (middle columns).
A–O, CB2 was observed in HLA-DR-positive microglia (A–C), CD68-positive macrophages (D–F ), MBP-containing macrophages
(G–I ), astrocytes (GFAP positive; J–L) and T-lymphocytes (M–O). Scale bar: 20m.
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the characteristic excitotoxic insult that is
triggered in neuroinflammatory condi-
tions, as well as by modulating the activity
of ion channels (Mechoulam et al., 2002).
Interestingly, CB1 receptors were also
present in adult oligodendrocytes and
OPCs located within MS plaques. These
cells are known to play a critical role in the
remyelination process that takes place
during the course of the disease (Levine et
al., 2001). It is important to note that we
reported previously that both CB1 and
CB2 receptors are expressed by different
rat oligodendrocyte subpopulations in
vivo and in vitro (Molina-Holgado et al.,
2002). Previous studies have shown that
cannabinoids act through both receptor-
dependent and -independentmechanisms
to promote oligodendrocyte survival
via a phosphatidylinositol 3-kinase/Akt-
dependent mechanism and thereby en-
hance axonal remyelination in an animal
model of MS (Molina-Holgado et al.,
2002; Arevalo-Martin et al., 2003).
Our data indicate that both CB1 and
CB2 receptors are present in microglia/
macrophages located in MS plaques.
These cells are thought to participate in
inflammatory processes and in the re-
moval ofmyelin and debris fromdamaged
cells (Bruck et al., 1996). The coexistence
of CB2 with intracellular MBP suggests
that the CB2-positive subset of macro-
phages were recently phagocytic and are
part of active plaques. Because immuno-
histochemical staining of MS lesions with
anti-myelin antibodies to estimate lesion
age is widely accepted (Bruck et al., 1995;
Noseworthy et al., 2000; Chang et al.,
2002; van der Goes et al., 2005), these data
provide evidence that the induction of
CB2 receptor expression in plaque-
associated macrophages could be an early
event in the maturation of MS plaques.
Although little is known regarding the ef-
fects of the cannabinoids on myelin
phagocytosis, it has been shown previ-
ously that activation of CB1 and CB2 receptors decreases the pro-
duction of proinflammatory cytokines in macrophages, indicat-
ing that an anti-inflammatory mechanism could potentiate the
neuroprotection induced by cannabinoids (Mestre et al., 2005;
Ortega-Gutierrez et al., 2005a). As reviewed by Croxford and
Yamamura (2005), several characteristics of macrophages, such as
migration, presentation of peptide antigens, or phagocytosis of for-
eign particles, are significantly influenced by cannabinoids.
The highest levels of CB2 receptor immunoreactivity were de-
tected in microglia, as observed previously by Yiangou et al.
(2006) in spinal cord sections from MS donors and in other hu-
man diseases with a neuroinflammatory component (Benito et
al., 2003, 2005). In addition, Maresz et al. (2005) have shown
previously that CB2 expression is upregulated in microglial cells
in autoimmune-induced inflammation of the CNS in mice. Our
results show that the distribution of these CB2-positive cells cor-
relates with that ofMHC-II-positive cells, whose localization and
abundance are used as defining markers of plaque subtype
(Trapp et al., 1999). Thus, MHC-II-positive cells are present
abundantly throughout the entire extension of acutely active
plaques, although these cells are restricted to the periphery of
chronically active plaques. The similarity between CB2-positive
cells and microglia and the colocalization of CB2 receptors with
HLA-DR leads us to postulate the presence of CB2 receptors as a
novel diagnostic marker for the identification of MS plaques of
the active type.
CB2 expression was also detected in white matter astrocytes.
To our knowledge, this is the first observation of an astrocytic
expression of these receptors in situ in the human CNS and con-
trast with previous data obtained in other pathologies such as
Alzheimer’s disease (Benito et al., 2003; Ramirez et al., 2005).
Little is known about the role that CB2 receptors play in astro-
Figure 3. CB1 distribution in MS samples. A, B, D, Subcortical white matter cells exhibited CB1 immunoreactivity (A, B);
CB1-positive cells (D) were identified as neurons by double staining with MAP-2 (E). G–I, Adult oligodendrocytes exhibited
cytoplasmic staining for CB1. J, K, Scarce OPCs in active plaques were positive for CB1 (J ) and PDGFR- (K ). Round-shaped
macrophages (CD68 positive; N ) also showed CB1 immunostaining (C,M ). Perivascular T-lymphocytes (Q; see vessel wall, arrow
in P) expressed CB1 receptors (P). Scale bars: A, 500m; B, 200m; C–F, 100m; G–R, 20m.
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cytes, although previous data suggest that theymaymodulate the
production of proinflammatory molecules in vitro (Ortega-
Gutierrez et al., 2005b; Sheng et al., 2005).
T-cells are known to participate in the pathogenesis ofMS (Fro-
hman et al., 2006). In particular, myelin-specific T-lymphocytes are
thought to be directly involved in the demyelinating process and to
cause inflammation. We have shown previously that cannabinoids,
acting throughbothCB1 andCB2 receptors, decreaseCD4
 infiltra-
tion into the spinal cord in an animalmodel ofMS (Arevalo-Martin
et al., 2003). As suggested previously, this could account for the
anti-inflammatory actionof cannabinoids.Thepresentdata corrob-
orate previous findings of the expression of both types of cannabi-
noid receptors in CNS-infiltrated T-lymphocytes (Benito et al.,
2005), particularly in perivascular fields. These data are highly sug-
gestive of a possible role of the ECS in MS-linked, T-cell-mediated
neuroinflammation.
Expression of the endocannabinoid-degrading enzyme FAAH
was increased in astrocytes within MS plaques compared with
control brain. This seems to be a strikingly constant feature of
FAAH, because reactive astrocytes exhibit increased expression
of this enzyme inAlzheimer’s disease samples (Benito et al., 2003)
as do perivascular astrocytes and astrocytic processes reaching
cellular infiltrates in an animal model of encephalitis (Benito et
al., 2005). Importantly, other arachidonic acid-related enzymes,
such as cyclooxygenase-2 and phospholipase-A2, are also known
to be selectively upregulated in astrocytes after inflammatory
stimuli (Sun et al., 2005). As suggested previously, FAAH inhibi-
tion could have beneficial effects during inflammation attribut-
able to both decreased local production of arachidonic acid and
enhanced endogenous cannabinoid tone (Benito et al., 2003; Ka-
ranian et al., 2005).
Although our study does not include a quantitative approach
attributable to the low number of cases and tissue availability, the
presence of different elements of the ECS in selective, specific, cell
types provide a neuroanatomical rationale for the effects of can-
nabinoids onMS symptoms and progression in humans. Possible
targets of ECS that could provide benefit for the treatment of MS
have focused only on CB1 activation so far. Our present results
allow us to postulate that other elements
of the ECS such as the CB2 receptors and
FAAH are potential therapeutic targets for
the treatment of MS in humans.
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